Stroke Trial, Recruiting NCT06725784 Sponsor: Swiss Federal Institute of Technology Condition: Stroke
Back to Stroke

Stroke Trial, Recruiting

NCT06725784
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who have signed a consent form agreeing to take part in the study.
  • People aged between 18 and 90 years old, of any gender.
  • People who have reduced function in one or both arms due to any illness or injury, where the treating clinicians believe the ReHandyBot therapy device could help improve that function.

Who may not be able to join:

  • People with medical conditions that could interfere with using the ReHandyBot training device (confirm with trial site for specific conditions that apply).

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 23 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Phone: 0041445107234

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Swiss Federal Institute of Technology
Registry
ClinicalTrials.gov
Start date
4 March 2025
Est. completion
30 December 2030

Where this trial is recruiting

🇨🇭 Switzerland

Primary endpoints

Cost of ReHandyBot; Cost of the clinical staff supporting therapy with ReHandyBot; Number of supervised therapy sessions with ReHandyBot; Number of minimally supervised therapy sessions with ReHandyBot; Number of unsupervised therapy sessions with ReHandyBot; Patient-to-therapist ratio of the therapy sessions with ReHandyBot

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 23 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov